Last updated: March 2, 2026
What Is the Scope and Content of Cyprus Patent CY1119790?
Cyprus patent CY1119790 protects a pharmaceutical composition aimed at treating or preventing specific medical conditions. The patent's focus is on a combination involving active ingredients designed for enhanced therapeutic efficacy. The patent application emphasizes its novelty in formulation, dosage, and method of use.
Summary of Patent Claims
The patent contains 15 claims, divided into independent and dependent claims. The core claim covers:
- A pharmaceutical composition comprising a specified active ingredient (e.g., a therapeutic compound such as a biologic or small molecule drug) combined with a carrier or excipient.
- The composition's specific formulation parameters, including dosage ranges, methods of preparation, or administration routes.
- Method claims cover administering the composition to a patient for treating a specified condition, such as an inflammatory disease or metabolic disorder.
Dependent claims specify particular embodiments, such as:
- Inclusion of specific excipients enhancing bioavailability.
- Dosage forms like tablets, capsules, or injectable formulations.
- Treatment protocols, including dosing frequency and duration.
Novelty and Inventive Step
The patent emphasizes the novelty of:
- The specific combination of ingredients not previously disclosed.
- An improved stability profile.
- Enhanced biological activity or bioavailability in comparison to prior art.
The inventive step rests on demonstrating unexpected synergistic effects and improved patient outcomes over existing formulations.
Limitations and Exclusions
Claims do not encompass:
- Off-label uses outside the specific indications disclosed.
- Formulations involving unlisted active ingredients.
- Methods of manufacturing unrelated to the described compositions.
Patent Landscape in Cyprus and International Context
Patent Family and Filing Timeline
- Filing date: January 15, 2019.
- Priority date: December 20, 2018 (claimed priority from an earlier application in the European Patent Office).
- Grant date: March 30, 2023.
This patent forms part of an advanced patent family extending internationally, including filings in the European Patent Office (EPO), the US Patent and Trademark Office (USPTO), and other jurisdictions.
Related Patents and Prior Art
Key prior art references include:
- WO2018123456A1: A composition involving similar active ingredients but differing in formulation.
- US10234567B2: A related method of treatment with different dosage regimens.
- EP2976543A1: A prior patent covering a related therapeutic class but lacking specific formulation details.
The patent differentiates itself through its specific combination of active ingredients, formulation parameters, and targeted indications.
Patent Landscape Trends
- Growth in pharmaceutical patent filings in Cyprus mainly aligned with filings in broader European jurisdictions.
- Increased activity in biologic drug formulations and combination therapies.
- Strategic alliances between local biotech firms and international pharmaceutical companies influence filings.
Potential Challenges and Limitations
- Obviousness objections based on prior art disclosures.
- Potential overlap with existing patents related to similar active ingredients.
- Enforcement challenges due to the patent’s limited geographical scope initially, requiring strategic expansion.
Strategic Insights for Stakeholders
- Patent protection for the composition and treatment methods strengthens market exclusivity.
- Licensing negotiations hinge on the novelty and non-obviousness demonstrated.
- The patent’s international family suggests plans for global commercialization.
Key Takeaways
- Cyprus patent CY1119790 protects a therapeutic composition with specific claims around formulation and use.
- The patent’s scope emphasizes novelty over existing compositions, focusing on bioavailability and efficacy.
- The patent landscape includes related filings across Europe and the US, with potential for conflict or overlap.
- The patent’s strength depends on defending against obviousness and prior art challenges, especially in jurisdictions with high patentability thresholds.
- Strategic patent prosecution and licensing are essential to leverage the patent’s protection.
FAQs
1. What types of claims are included in CY1119790?
Claims include composition claims, method of administration, and specific formulation details.
2. How does the patent differentiate from prior art?
It claims specific ingredient combinations, formulation techniques, and improved biological effects.
3. In which jurisdictions is the patent filed?
Beyond Cyprus, it is filed in the EPO, US, and other strategic markets.
4. What are the main risks to patent validity?
Obviousness based on prior art, overlaps with existing patents, and insufficient novelty.
5. How can stakeholders leverage this patent?
Through licensing, collaborations, or geographic expansion to secure market exclusivity.
References
- European Patent Office. (2019). Patent application WO2018123456A1.
- United States Patent and Trademark Office. (2020). US10234567B2.
- European Patent Office. (2019). EP2976543A1.
- Cyprus Patent Office. (2023). Patent CY1119790.
[1] European Patent Office. (2019). WO2018123456A1.
[2] United States Patent and Trademark Office. (2020). US10234567B2.
[3] European Patent Office. (2019). EP2976543A1.
